ReviewCurrent atherosclerosis reports2026
Non-HDL Cholesterol as a Predictor of Coronary Atherosclerosis in South Asians: A Narrative Review.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo examine the role of non-HDL cholesterol (non-HDL-C) as a predictor of coronary atherosclerosis and atherosclerotic cardiovascular disease (ASCVD) risk in South Asians, and its utility relative to LDL-C and apolipoprotein B for risk stratification and lipid-lowering therapy in this high-risk population. RECENT
findingsSouth Asians experience a disproportionate and premature burden of ASCVD that is not fully explained by conventional risk factors and is underestimated by most established risk calculators. They exhibit a characteristic atherogenic dyslipidemia - elevated triglycerides, low HDL-C, and a predominance of small dense LDL and remnant particles, often with only modestly elevated LDL-C - that is inadequately captured by LDL-C but well reflected in non-HDL-C. Non-HDL-C demonstrates a graded association with ASCVD, correlates with atherosclerotic plaque burden across imaging modalities (coronary artery calcium, coronary CT angiography, and intravascular ultrasound), and has outperformed LDL-C for risk prediction in large meta-analyses. Recent US and Indian guidelines now incorporate non-HDL-C as a coprimary treatment target, with the Lipid Association of India providing South Asian-specific thresholds. Non-HDL-C is an inexpensive, non-fasting lipid measure that better captures the atherogenic lipoprotein burden of South Asians than LDL-C alone and may improve risk stratification and treatment in this group. Data specific to non-HDL-C in South Asians remain limited; future work should define population-specific thresholds, clarify its relationship with apolipoprotein B and lipoprotein(a), and address the under-representation of South Asians in clinical trials and persistent barriers to preventive care.
Indexed as
Identifiers
42814261What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.